---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267758"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:54:40.863252+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics appoints Esther Rajavelu as CFO and CBO effective Nov 6

## Summary
- Esther Rajavelu appointed CFO and Chief Business Officer; assumes principal financial officer role after Q3 10-Q filing.
- Annual base salary of $475,000; sign-on bonus of $50,000; target annual cash bonus of 40% of base salary.
- Grant of 300,000 RSUs under inducement plan, vesting in equal annual installments over four years starting Nov 6, 2024.
- Interim CFO Stephen DiPalma continues until Q3 10-Q filed; may consult post-transition.

## SEC filing metadata
- accession: 0001193125-23-267758
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/0001193125-23-267758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/d506257d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267758
- JSON: https://secwatch.observer/filing/0001193125-23-267758.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267758.txt

## Key facts
- Executive change
  Esther Rajavelu was appointed as Chief Financial Officer and Chief Business Officer at Spero Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Chief Business Officer
  source text: On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/0001193125-23-267758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.